News coverage about CASI Pharmaceuticals (NASDAQ:CASI) has trended positive recently, according to Accern. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. CASI Pharmaceuticals earned a media sentiment score of 0.27 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 46.5519393397905 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the media stories that may have impacted Accern Sentiment’s analysis:
- CASI Pharmaceuticals, Inc. (CASI) Given $3.50 Consensus Price Target by Brokerages (americanbankingnews.com)
- Overstock.com, Inc., (NASDAQ: OSTK), CASI Pharmaceuticals, Inc., (NASDAQ: CASI), Palo Alto Networks, Inc., (NYSE … – Stocks In The News (press release) (tradingnewsnow.com)
- CASI Pharmaceuticals : Reports Third Quarter 2017 Financial Results (4-traders.com)
- CASI Pharmaceuticals Inc. (NASDAQ:CASI) Reports Narrow Q3 Net Loss – Stock News Union (blog) (stocknewsunion.com)
CASI has been the subject of several research analyst reports. ValuEngine upgraded shares of CASI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, September 15th. Maxim Group restated a “buy” rating and issued a $4.00 price target on shares of CASI Pharmaceuticals in a research report on Friday, September 8th. Finally, HC Wainwright restated a “buy” rating and issued a $2.00 price target on shares of CASI Pharmaceuticals in a research report on Friday, September 8th.
CASI Pharmaceuticals (NASDAQ:CASI) last released its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.01. equities analysts expect that CASI Pharmaceuticals will post -0.15 earnings per share for the current year.
In related news, Director Wei-Wu He bought 100,000 shares of the business’s stock in a transaction on Tuesday, October 10th. The stock was bought at an average price of $1.95 per share, for a total transaction of $195,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In the last quarter, insiders acquired 996,329 shares of company stock valued at $1,647,138. Insiders own 24.52% of the company’s stock.
CASI Pharmaceuticals Company Profile
CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.
Receive News & Ratings for CASI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.